Related Experiment Video

Updated: Jan 12, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1-Positive Metastatic NSCLC

Omar K Abughanimeh Mbbs, Anthony E Maida Iii PhD Ma Mba, Sanjive Qazi PhD

    Oncology (Williston Park, N.Y.)
    |October 31, 2025
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
    07:42

    Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

    Published on: February 7, 2021

    5.6K
    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    1.0K

    Related Experiment Videos

    Last Updated: Jan 12, 2026

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
    07:43

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

    Published on: September 25, 2018

    11.0K
    Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
    07:42

    Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

    Published on: February 7, 2021

    5.6K
    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    1.0K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.7K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.7K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    5.9K
    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.9K

    Articles linked to this work by shared authors, journal, and citation graph.

    Persistent differences in aerobic physical activity guideline adherence among U.S. cancer survivors: Evidence from the national health interview survey, 2010-2020.

    Journal of cancer survivorship : research and practice·2026

    Current Status of Immunotherapy in Resectable Lung Cancer.

    Indian journal of surgical oncology·2026

    Outcomes Based on Age in CALGB 140503 (Alliance): Lobar Versus Sublobar Resection for Peripheral Stage IA Non-small Cell Lung Cancer.

    Clinical lung cancer·2026

    Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors.

    Clinical lung cancer·2026

    Perceived Barriers and Facilitators to Physical Activity Engagement Among Cancer Survivors: A Qualitative Study.

    Cancers·2026

    Ixazomib triggers autophagic degradation of MUC5AC/integrin-β4 and inhibits non-small cell lung cancer progression.

    Cancer letters·2026

    Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer.

    Oncology (Williston Park, N.Y.)·2026

    Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City.

    Oncology (Williston Park, N.Y.)·2026

    Access to Care and Drug Prices: Recent Department of Health and Human Services Guidance.

    Oncology (Williston Park, N.Y.)·2026

    Clinical Outcomes of Acute Pancreatitis in Patients With Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026

    Primary Malignant Melanoma of the Colon: A Rare and Challenging Diagnosis.

    Oncology (Williston Park, N.Y.)·2026

    Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026

    Amount and Burden of Brain Tissue Hypoxia to Determine Clinical Efficacy of Secondary Decompressive Craniectomy After Moderate/Severe Traumatic Brain Injury.

    Neurosurgery·2026

    The effects of epicatechin on oxidative stress and genotoxicity induced by cypermethrin in PC-12 cell line.

    Drug and chemical toxicology·2026

    Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer.

    The Laryngoscope·2026

    Radiotherapy and immunotherapy in cancer treatment: mechanisms of clinical synergy.

    The Journal of clinical investigation·2026

    Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

    Expert review of pharmacoeconomics & outcomes research·2026

    Robotic radical thymectomy using the Hugo RAS system - a step-by-step right thoracic approach.

    Multimedia manual of cardiothoracic surgery : MMCTS·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us